NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature

References

• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13. PubMed PMID: 20213383.
   Google Scholar
• Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010 Oct;810:705–718. PubMed PMID: 21317869.
   Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015 Sep 20;33(27):3029–3035. PubMed PMID: 26304877; PubMed Central PMCID: PMCPMC4979196.
   Google Scholar
• Goodman AM, Piccioni D, Kato S, et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 2018 Sep 1;4(9):1237–1244. PubMed PMID: 29902298; PubMed Central PMCID: PMCPMC6139049.
   Google Scholar
• Lussier DM, Johnson JL, Hingorani P, et al. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3:21. PubMed PMID: 25992292; PubMed Central PMCID: PMCPMC4437699.
   Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493–1501. PubMed PMID: 28988646.
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jul 11;369(2):122–133. PubMed PMID: 23724867; PubMed Central PMCID: PMCPMC5698004.
   Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–1290. PubMed PMID: 29562145; PubMed Central PMCID: PMCPMC5972549.
   Google Scholar
• Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014 Nov;14(11):722–735. PubMed PMID: 25319867.
   Google Scholar
• Lussier DM, O’Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J ImmunoTher (Hagerstown, Md: 1997). 2015 Apr;38(3):96–106. PubMed PMID: 25751499; PubMed Central PMCID: PMCPMC6426450.
   Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275–4280. PubMed PMID: 20160101; PubMed Central PMCID: PMCPMC2840093.
   Google Scholar
• Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec;15(4):658–669. PubMed PMID: 25096781; PubMed Central PMCID: PMCPMC4216599.
   Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016 Dec;17(12):e542–e551. PubMed PMID: 27924752; PubMed Central PMCID: PMCPMC5702534.
   Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847–856. PubMed PMID: WOS:000358052500001; English.
   Google Scholar
• Koirala P, Roth ME, Gill J, et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep. 2016 Jul;26(6):30093. PubMed PMID: 27456063; PubMed Central PMCID: PMCPMC4960483.
   Google Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014 Jul;2(7):690–698. PubMed PMID: 24866169; PubMed Central PMCID: PMCPMC4082476.
   Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017 Jul 28;357(6349):409–413. PubMed PMID: 28596308; PubMed Central PMCID: PMCPMC5576142.
   Google Scholar
• Martin SS, Hurt WG, Hedges LK, et al. Microsatellite instability in sarcomas. Ann Surg Oncol. 1998 Jun;5(4):356–360. PubMed PMID: WOS:000073985500011; English.
   Google Scholar
• Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: accelerating progress makes for a hopeful future. Front Oncol. 2018;8:4. PubMed PMID: 29435436; PubMed Central PMCID: PMCPMC5790793.
   Google Scholar
• Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014 Apr 10;7(1):104–112. PubMed PMID: 24703847; PubMed Central PMCID: PMCPMC4096827.
   Google Scholar
• Mansfield AS, Murphy SJ, Peikert T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 2016 May 1;22(9):2177–2182. PubMed PMID: WOS:000375329100013; English.
   Google Scholar
• Boddu S, Walko CM, Bienasz S, et al. Clinical utility of genomic profiling in the treatment of advanced sarcomas: a single-center experience. Jco Precis Oncol. 2018 Oct 19;2. PubMed PMID: WOS:000462145400001; English. DOI:10.1200/Po.18.00261
   Google Scholar
• Groisberg R, Roszik J, Conley A, et al. The role of next-generation sequencing in sarcomas: evolution from light microscope to molecular microscope. Curr Oncol Rep. 2017 Oct 13;19(12):78. PubMed PMID: 29030741.
   Google Scholar
• Cote GM, He J, Choy E. Next-generation sequencing for patients with sarcoma: a single center experience. Oncologist. 2018 Feb;23(2):234–242. PubMed PMID: WOS:000425135900016; English.
   Google Scholar